{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:46:01Z","timestamp":1791870361875,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaci.2026.02.041","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:06:58Z","timestamp":1773158818000},"page":"1009-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Food and Drug Administration regulation of biosimilar products: Improving affordability of biologics for patients with asthma and allergic diseases"],"prefix":"10.1016","volume":"157","author":[{"given":"Sabiha","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Herndon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjeni","family":"Keswani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Clarridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak S.","family":"Pisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrahas","family":"Sahajwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4434-5032","authenticated-orcid":false,"given":"Kelly D.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.02.041_bib5","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.jaip.2022.09.005","article-title":"Overview of FDA drug approval and labeling","volume":"10","author":"Clarridge","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.02.041_bib12","unstructured":"Section 7002(a)(2) of the Affordable Care Act, adding section 351(k)(2)(A)(i)(I) of the PHS Act."},{"key":"10.1016\/j.jaci.2026.02.041_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.832059","article-title":"Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms","volume":"10","author":"Nupur","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.jaci.2026.02.041_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292231","article-title":"Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis","volume":"18","author":"Herndon","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2026.02.041_bib18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jama.2024.15225","article-title":"The science of biosimilars\u2014updating interchangeability","volume":"332","author":"Cavazzoni","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2026.02.041_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.09.006","article-title":"Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial","author":"Bielsky","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jaci.2026.02.041_bib25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40259-023-00631-4","article-title":"Do the outcomes of clinical efficacy trials matter in regulatory decision-making for biosimilars?","volume":"37","author":"Kirsch-Stefan","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaci.2026.02.041_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-025-02168-y","article-title":"The tailored biosimilar approach: expectations and requirements","volume":"85","author":"Guillen","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2026.02.041_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaci.2026.02.041_bib31","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.41203","article-title":"Failure to launch: biosimilar sales continue to fall flat in the United States","volume":"72","author":"Yazdany","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492600182X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492600182X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:39:28Z","timestamp":1781685568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167492600182X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S009167492600182X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.02.041","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Food and Drug Administration regulation of biosimilar products: Improving affordability of biologics for patients with asthma and allergic diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.02.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}